Article Text

Download PDFPDF
Digoxin for rheumatic heart disease: a cautious future for a drug from the past?

Statistics from Altmetric.com

Footnotes

  • Contributors BRN and AZB participated in literature review, analysis of the original manuscript, drafting and reviewing the final version of the editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data sharing statement The data analytic methods and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure, from the corresponding author on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Valvular heart disease
    Ganesan Karthikeyan Niveditha Devasenapathy Liesl Zühlke Mark Emmanuel Engel Sumathy Rangarajan Koon K Teo Bongani M Mayosi Salim Yusuf on behalf of the Global Rheumatic Heart Disease Registry (REMEDY) Investigators Azza Abul Fadl Sahar S Sheta Abraham Haileamlak Senbeta G Abdissa Dufera M Begna Wandimu Daniel Araya G Desta Dejuma Yadeta Goshu Bekele A Shasho Bernard Gitura Stephen Ogendo Neil Kennedy Albertino Damasceno Ana Olga Mocumbi Christopher Hugo-hamman Dike Ojji Ganiyu A Amusa Fidelia Bode-thomas Christopher C Yilgwan Olukemi Ige Basil Okeahialam Mahmoud U Sani Okechukwu S Ogah Taiwo Olunuga Abiodun M Adeoye Okechukwu Ogah Joseph Mucumbitsi Blanche Cupido Phindile Mntla Christopher Sutton Rajeev Misra Ahmed Elsayed Ahmed S Ibrahim Huda H M elhassan Peter Lwabi Charles Mondo Emmy Okello Mohammed M Al-kebsi John Musuku